Zacks cuts Gilead to Hold as Gilead Sciences stock costs EUR 128.93
Published on 10/06/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock costs EUR 128.93 at Lang & Schwarz on October 6, 2026 at 11:09 a.m. CEST, up 0.11 percent versus the prior close of EUR 128.79. As MarketBeat reported on October 1, 2026, Zacks Research downgraded Gilead Sciences from strong buy to hold. The rating change contrasts with a broader positive analyst consensus.
Zacks rating meets a stronger consensus
MarketBeat said 23 analysts rated the stock Buy and six rated it Hold, producing a Moderate Buy consensus and an average target of USD 158.78. The consensus figure is stated in US dollars and therefore is not directly compared with the Lang & Schwarz euro quote.
A separate Marketscreener report dated September 10, 2026 said HSBC raised its target from USD 155.00 to USD 175.00 while keeping a Buy rating. That target action provides a more constructive counterpoint to the Zacks downgrade.
HIV sales lift the 2026 outlook
In the second quarter of 2026, revenue reached USD 7.80 billion, up 10.00 percent year over year, according to Zacks. The result exceeded its consensus estimate of USD 7.37 billion, while product sales excluding Veklury rose 10.00 percent to USD 7.60 billion.
The second-quarter 2026 earnings call reported HIV sales of USD 5.70 billion, up 12.00 percent year over year, and Biktarvy sales of USD 3.80 billion, up 7.00 percent. Fortune reported that management raised full-year 2026 HIV sales growth guidance to 9.00-10.00 percent from 8.00 percent.
For investors, the key tension is visible in the mix: HIV sales grew 12.00 percent in the second quarter, while the rating downgrade highlights expectations after a strong run. The company is therefore being judged on whether new prevention products can extend growth beyond its established treatment base.
Gilead stock stays above its prior close
Gilead Sciences had a market capitalization of USD 179.3 billion and a 52-week range of USD 112.82 to USD 157.29 as of October 5, 2026. The Lang & Schwarz quote remained above its prior close during the October 6, 2026 session, with the intraday change limited to plus 0.11 percent.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 6, 2026, 11:09 a.m. CEST: EUR 128.93
- Change versus prior close: plus 0.11 percent
- Prior close Lang & Schwarz October 5, 2026: EUR 128.79
- Market capitalization: USD 179.3 billion as of October 5, 2026
- 52-week range: USD 112.82-157.29 as of October 5, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - General
